Rani Therapeutics
RANI
34 hedge funds and large institutions have $6.96M invested in Rani Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0.15% less ownership
Funds ownership: 12.72% → 12.57% (-0.15%)
3% less funds holding
Funds holding: 35 → 34 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
47% less capital invested
Capital invested by funds: $13.3M → $6.96M (-$6.29M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$249K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$197K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$133K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.8K |
| 5 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$37.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$334K |
| 2 |
HF
HRT Financial
New York
|
-$170K |
| 3 |
Renaissance Technologies
New York
|
-$142K |
| 4 |
ASGS
Alpha Square Group S
New York
|
-$55.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$36.9K |
RANI Hedge Fund Activity: Q3 2023 in Review
34 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q3 2023, worth a combined $6.96M — down 47% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RANI and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 6 added.
The largest buyer was Stifel Financial, adding an estimated $249K. The largest seller was Millennium Management, cutting an estimated $334K.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q3 2023, down from 35 in Q2 2023.
- Funds reported $6.96M of Rani Therapeutics stock for Q3 2023, down 47% quarter-over-quarter.
- 3 funds opened new Rani Therapeutics positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Rani Therapeutics buyer in Q3 2023 was Stifel Financial, an estimated $249K added.
- The largest Rani Therapeutics seller in Q3 2023 was Millennium Management, an estimated $334K sold.
Based on aggregated 13F filings for Q3 2023.